Researchclopedia
Research
Researchers
Institutions
Topics
Submit
About
Search...
⌘
K
Command Palette
Search for a command to run...
Back to research
LRRK2-targeting antisense oligonucleotide in Parkinson’s disease: a phase 1 randomized controlled trial
2026
0 citations
Journal Article
Field-Weighted Citation Impact:
0.00
LRRK2-targeting antisense oligonucleotide in Parkinson’s disease: a phase 1 randomized controlled trial | Researchclopedia
·
Biogen (United States)
Roy Llorens Arenas
·
Biogen (United States)
John W. Annand
·
Biogen (United States)
Unnati Kapadnis
·
Biogen (United States)
Alan A. Shomo
·
Biogen (United States)
Kelly E. Glajch
·
Biogen (United States)
Kyle Ferber
·
Biogen (United States)
Yuka Moroishi
·
Biogen (United States)
Julie Czerkowicz
·
Biogen (United States)
Jennifer Inra
·
Biogen (United States)
Ronald B. Postuma
·
Montreal Neurological Institute and Hospital
Tanya Gurevich
·
Tel Aviv Sourasky Medical Center
Pablo Mir
·
Instituto de Salud Carlos III
Huw R. Morris
·
National Hospital for Neurology and Neurosurgery
Jason Aldred
·
Inland Northwest Health Services
Matthew A. Brodsky
·
Oregon Health & Science University
Aaron Ellenbogen
·
Michigan Institute for Neurological Disorders
Danielle Larson
·
Northwestern University
Christopher M. Tolleson
·
University of Tennessee Medical Center
Andrew Siderowf
·
University of Pennsylvania
Charalampos Tzoulis
·
Haukeland University Hospital
Ernest Balaguer
·
Hospital General de Catalunya
Maria J. Marti
·
Hospital Clínic de Barcelona
Hien T. Zhao
·
Ionis Pharmaceuticals (United States)
Holly B. Kordasiewicz
·
Ionis Pharmaceuticals (United States)
Roger Lane
·
Ionis Pharmaceuticals (United States)
Warren D. Hirst
·
Biogen (United States)
Stephanie Fradette
·
Biogen (United States)
Danielle L. Graham
·
Biogen (United States)